Kinetics of IgA Subtypes and Cytokines in Respiratory Secretions Following Immunization With COVID-19 Mucosal Vaccine.

ABSTRACT: The COVID-19 pandemic highlights the need for mucosal vaccines inducing respiratory secretory IgA (sIgA), as traditional intramuscular vaccines primarily elicit systemic IgG with limited mucosal protection. This study systematically compared mucosal immune responses induced by two authorized COVID-19 mucosal vaccines: an orally aerosolized adenovirus vector-based vaccine (Ad5-nCoV) and an intranasal live-attenuated influenza virus vector-based vaccine (dNS1-RBD). We longitudinally assessed IgA, IgA1, and IgA2 antibody titers against SARS-CoV-2 RBD/Spike protein, alongside cytokine profiles, in nasal secretions and sputum from 40 participants at 7, 14, 28 days, and 3/6 months post-immunization. The orally aerosolized vaccine exhibited superior mucosal immunogenicity, with peak IgA positive

SUBMITTER: Chen W 

PROVIDER: S-EPMC12517115 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature